Acquisition by Tammenoms Bakker Juliet of 5731 shares of Rxsight subject to Rule 16b-3
| RXST Stock | USD 30.39 0.79 2.53% |
Slightly above 62% of Rxsight's investor base is looking to short. The analysis of overall sentiment of trading Rxsight stock suggests that many investors are alarmed at this time. Rxsight's investing sentiment can be driven by a variety of factors including economic data, Rxsight's earnings reports, geopolitical events, and overall market trends.
Rxsight |
Filed transaction by Rxsight Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Rxsight Fundamental Analysis
We analyze Rxsight's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rxsight using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rxsight based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Rxsight is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Rxsight Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Rxsight stock to make a market-neutral strategy. Peer analysis of Rxsight could also be used in its relative valuation, which is a method of valuing Rxsight by comparing valuation metrics with similar companies.
Peers
Rxsight Related Equities
| TMCI | Treace Medical | 5.58 | ||||
| KIDS | Orthopediatrics Corp | 2.37 | ||||
| FNA | Paragon 28 | 2.06 | ||||
| CVRX | CVRx | 1.85 | ||||
| IRMD | Iradimed | 1.39 | ||||
| OFIX | Orthofix Medical | 1.12 | ||||
| NPCE | Neuropace | 0.50 | ||||
| SGHT | Sight Sciences | 0.35 | ||||
| VREX | Varex Imaging | 1.10 | ||||
| SIBN | Si Bone | 1.36 | ||||
| SSKN | STRATA Skin | 1.69 | ||||
| AXGN | Axogen | 1.84 | ||||
| APYX | Apyx Medical | 2.11 | ||||
| LUNG | Pulmonx Corp | 2.19 |
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.